NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
ID: 358045Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358045

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-335.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Translational Research Program for Therapeutics, aimed at advancing innovative therapies for visual system diseases. This program utilizes a bi-phasic R61/R33 grant mechanism, where the R61 phase supports the refinement of preliminary data, and the R33 phase focuses on advancing promising candidates through FDA regulatory processes leading to Investigational New Drug (IND) applications. The initiative encourages multidisciplinary collaboration among scientists, clinicians, and regulatory experts, with a budget cap of $500,000 for R61 applications and $1,000,000 for R33 applications. Interested applicants must submit their proposals by March 17, 2025, with the program opening for applications on January 16, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-335-Full-Announcement.html
    PAR-25-335.html
    The National Eye Institute (NEI), under the Department of Health and Human Services, is soliciting proposals for its Translational Research Program targeting innovative therapy development for visual system diseases. The funding opportunity aims to transition preclinical research findings into therapeutic applications, with a bi-phasic R61/R33 approach. The R61 phase supports preliminary data refinement, while the R33 phase focuses on advancing promising candidates through FDA regulatory studies leading to Investigational New Drug (IND) applications. Eligible organizations include educational institutions and nonprofits, among others, with a budget cap of $500,000 for R61 applications and $1,000,000 for R33 applications. The initiative seeks multidisciplinary collaboration among scientists, clinicians, and regulatory experts to explore therapies for conditions like retinal diseases and glaucoma. Applications must conform to strict guidelines, including the establishment of clear milestones, and failure to meet these criteria can result in rejection. Key dates include an application due date of March 17, 2025, opening on January 16, 2025. The program emphasizes diversity among applicants to enhance scientific innovation and effectiveness. This funding opportunity reflects the NEI's commitment to advancing eye health through the development of novel therapeutic solutions.
    Similar Opportunities
    NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed). This grant aims to support meritorious research projects that utilize existing databases for secondary data analyses related to vision health, with a focus on enhancing statistical methodologies for analyzing vision data. The initiative is crucial for addressing major causes of blindness and improving the understanding of visual system development and function. Eligible applicants include a wide range of institutions, and the total project budget can reach up to $275,000 over two years. Interested parties should submit their applications by October 16, 2027, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-357.html.
    NEI Collaborative Clinical Vision Research Project: Resource Center Grant (UG1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Collaborative Clinical Vision Research Project, specifically for Resource Center Grants (UG1 Clinical Trial Required). This initiative aims to support large-scale clinical trials focused on screening, diagnosing, preventing, or treating vision disorders, with a particular emphasis on evaluating complex interventions and providing essential services for multi-center trials. The NEI seeks to advance vision health through rigorous research, and applications are encouraged from a diverse range of eligible applicants, including various educational institutions and organizations. Interested parties must submit their applications by May 25, 2026, and can find additional information and guidelines at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44), aimed at supporting small business concerns (SBCs) conducting early-stage clinical trials related to vision disorders. Applicants are required to propose studies that evaluate interventions for screening, diagnosing, preventing, or treating eye diseases, with a focus on trials that typically fall under Phase I or II and involve greater than minimal risk, necessitating appropriate oversight and safety monitoring. This initiative underscores the government's commitment to advancing clinical research and innovation in vision health, with applications due by January 7, 2027. Interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-066.html.
    NEI Collaborative Clinical Vision Research: Chair's Grant (UG1-Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Eye Institute (NEI), has announced a Notice of Funding Opportunity (NOFO) for the NEI Collaborative Clinical Vision Research: Chair's Grant (UG1), aimed at supporting large-scale clinical trials focused on vision disorders. This funding opportunity is intended for projects that evaluate interventions for screening, diagnosing, preventing, or treating vision disorders, specifically requiring a clinical trial with a clear scientific rationale and detailed study design. The NEI emphasizes the importance of these trials in advancing vision science and public health, with awards structured as cooperative agreements to ensure substantial NIH involvement in the research process. Interested applicants must submit their proposals by May 25, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NEI Collaborative Clinical Vision Research Project, specifically seeking applications for a Coordinating Center grant under the UG1 activity code. This initiative aims to support large-scale, investigator-initiated clinical trials focused on vision disorders, including interventions for screening, diagnosing, preventing, or treating these conditions, with an emphasis on projects that require significant oversight and management. The NEI's mission is to advance vision research and enhance public health through rigorous clinical trials, ensuring compliance with NIH policies and ethical standards in research involving human subjects. Interested applicants, including a diverse range of organizations such as higher education institutions and nonprofits, must submit their applications by May 25, 2026, and can find further details at the provided NIH grants information email: grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Vision Health Equity through Multi-level Interventions and Community-Engaged Research (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at advancing vision health equity through multi-level interventions and community-engaged research. This initiative, led by the National Eye Institute (NEI) in collaboration with other NIH Institutes and Centers, seeks to solicit applications for research projects that address disparities in vision health. The funding opportunity is significant, with an estimated total program funding of $7 million and an award ceiling of $1 million, expecting to support approximately six awards. Interested applicants should note that the NOFO is anticipated to be published in Winter 2025, with applications due in early Spring 2025, and the estimated award date is set for December 1, 2025.
    NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NEI Center Core Grant for Vision Research, aimed at enhancing collaborative vision research through shared resource and service cores for funded investigators. This grant supports institutions with eight or more active NEI-supported R01 grants, providing direct costs of up to $2 million or $2.5 million over five years, depending on the number of eligible grants at the institution. The program is designed to increase productivity and collaboration among researchers while offering high-quality services that would be too costly for individual projects, ultimately supporting the NEI's mission to advance understanding of vision disorders. Applications are due by September 30, 2023, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) funding opportunity, aimed at supporting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies of therapeutic agents for neurological and neuromuscular disorders. This grant follows the R61/R33 phased award mechanism, where the R61 phase focuses on preparation and characterization, while the R33 phase emphasizes efficacy studies, with a critical transition contingent upon meeting specific milestones. The program encourages collaboration among various organizations, including nonprofit entities and academic institutions, to accelerate the development of promising therapies, with awards capped at $750,000 over a maximum project duration of three years. Interested applicants can find more information and application instructions at the NIH grants website, and the deadline for submissions is October 20, 2027.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)." This initiative aims to foster collaborations between academic and industrial entities to develop innovative solutions for critical health challenges, particularly in the fields of cancer and eye health. The program encourages interdisciplinary research teams to enhance and validate technologies that improve diagnostic methods and treatment capabilities, ultimately supporting better health outcomes for diverse populations. The funding amount is capped at $499,000 annually, with a maximum project duration of five years. Initial submissions are due by January 5, 2025, and interested applicants can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)." This initiative aims to support the characterization and efficacy studies of neurotherapeutic agents intended for treating neurological disorders, with a focus on conducting pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate the biological activity of proposed therapeutic agents. The program emphasizes the importance of rigorous experimental design, collaboration, and the inclusion of diverse perspectives in research teams, aligning with NIH's mission to translate research discoveries into effective therapies. Interested applicants can apply for funding up to $499,000 per year for a total project duration not exceeding three years, with the application deadline set for October 20, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-225.html.